This study tests a new drug, **MBRC-101**, for patients with advanced cancer that no longer responds to treatment. The study has three parts: **Phase 1**, **Phase 1b**, and **Phase 2**. In **Phase 1**, 30 patients will help find the best safe dose. **Phase 1b** will test this dose on 60 more patients in three groups. **Phase 2** will check how well the drug works on the specific tumor type found in the earlier phases, with about 30 patients taking part. Patients must be 18 or older, have no other treatment options, and meet health criteria. They must agree to use contraception, and women should not be pregnant or breastfeeding. The study checks MBRC-101's safety and how long it stays in the body. Patients will have regular scans like MRI or CT to see if the drug is working. **Key Points:**

• Study involves a series of phases to determine safety and effectiveness.
• Participants must be 18+, with no standard treatment options available.
• Safety is monitored regularly throughout the study.